Skip to content
Subscriber Only

Myriad Genetics Sues Ambry to Thwart Breast Cancer Test

Myriad Genetics Inc., a provider of tests for breast-cancer risk, is asking a federal court to stop two competitors that set up shop after a mixed U.S. Supreme Court ruling last month on patenting human genes.

Ambry Genetics Corp., a closely held clinical laboratory in Aliso Viejo, California, and Houston-based Gene By Gene Ltd., said June 13 they would offer the breast and ovarian cancer tests hours after a high court ruling that invalidated some of Myriad’s patents on genes linked to the diseases. The tests look at genes known as BRCA to determine if there is a hereditary risk of developing the diseases.